Infantile hemangioma. 17 cases treated with propranolol
Main Article Content
Abstract
Introduction: Hemangioma of infancy is a benign and self-limiting tumor; however the lesion can be severely invasive or very deforming. Objective: To report the evolution of hemangioma of infancy treated with oral propranolol. Patients and Methods: Between March 2010 and February 2017, children with hemangioma of infancy who had used propranolol at a dose of 1 mg/kg/day, in two doses and who, subsequently, had the propranolol dose increased to 2 mg/kg/day were followed up at an outpatient clinic of a university hospital. Children with bronchial asthma and allergic rhinitis were excluded. Results: In the 17 cases studied, the age of diagnosis varied from 1 to 12 months old
(median: 3 months old). The age of onset of treatment varied between 1 and 18 months old (median: 4 months old). The patients were followed up until marked decrease or resolution of the lesion, which lasted from 2 to 38 months (median: 28 months). There were no complications during the evolution. Conclusion: oral propranolol proved to be safe and effective in resolving hemangioma of infancy visible to ectoscopy.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
1. Kassarjian A, Zurakowski D, Dubois J, Paltiel HJ, Fishman SJ, Burrows P.E. Infantile hepatic hemangiomas: clinical and imaging findings and their correlation with therapy Am J Roentgenol. 2004;182 (3):785-79.
2. Frieden IJ, Haggstrom AN, Drolet BA, Mancini AF, Friedlander SF, Boon L, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol. 2005(5);22: 383-406.
3. Smith SSK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002;38(5):298-304.
4. Yao TH, Pataer P, Regmi KP, Gu XW, Li QY, Du JT, et al. Propranolol induces hemangioma endothelial cell apoptosis saw p53 BAX mediated pathway. Mol Med Rep. 2018 May 14. DOI: 10.3892/mmr.2018.9013
5. Ma EH, Robertson SJ, Chow CW, Bekhor PS. Infantile hemangioma with minimal or arrest growth. Further observations on clinical and histopathologic findings of this unique but underrecognized entity. Pediatr Dermatol. 2017;34(1): 64-71.
6. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope. 2009;119(10):2051-4.
7. Zaher H, Rasheed H, El-Komy MM, Hegazy RA, Gawdat HI, Abdel Halim DM, et al. Propranolol versus captopril in the treatment of infantile hemangioma: A randomized controlled trial. J Am Acad Dermatol. 2016;74(3): 499-505.
8. Aly MM, Hamza AF, Abdel Kader HM, Saafan HA, Ghazy MS, Ragab IA. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr. 2015; 174(11):1503-9.
9. Ballona R, Zevallos J, Nunez J. Clinical evaluation of infantile hemangiomas treated with atenolol. Dermatol Online J. 2020;26(12): 13030/qt0xf7g59m.
10. Zhang L, Wu HW, Yuan W, Zheng JW. Propranolol therapy for infantile hemangioma: our experience. Drug Des Devel Ther. 2017; 11:1401-1408.
11. Price A, Rai S, Mcleod RWJ, Birchall JC, Elhassan HA. Topical propranolol for infantile haemangiomas: a systematic review. J Eur Acad Dermatol Venereol. 2018;32(12):2083-2089.
12. Mannschreck DB, Huang AH, Lie E, Psoter K, Puttgen K. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2019. DOI: 10.1111/pde.13816.